CSBJ earned a 2025 Impact Factor of 4.8 and a CiteScore of 8.2. It is an honor to be part of the journal and contribute to its continued success.
SHARE
Researchers in Professor George Church’s laboratory at Harvard Medical School, in collaboration...
On August 26, 2026, the FDA approved Rasonque (daraxonrasib) for adults with...
After mRNA vaccines achieved remarkable success during the COVID-19 pandemic a few...
